# US 2013/0252974 A1 · 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as urotensin ii receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252974 A1
- Document ID: US20130252974A1
- Status: Published application
- Kind: A1
- Application number: 13/894,872
- Filed: 2013-05-15
- Published: 2013-09-26
- Earliest claimed: 2008-02-07
- Assignees: Sanofi
- Inventors: Jean-Michel Altenburger; Valerie Fossey; Daniel Galtier; Frederic Petit
- Web page: https://patentgrep.com/patent/US20130252974A1

## CPC

- C07D 213/81: Amides; Imides
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/48: of the pancreatic hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/60: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists.

## Claims

### Claim 1

A compound corresponding to formula (I)
in which:
X and Y represent, independently of each other, a nitrogen atom or —CR4-, in which R4 represents a hydrogen atom or a (C1-C4) alkyl or alkoxy group;
A represents a fused aryl, unfused aryl, or heteroaryl group, said aryl or heteroaryl group optionally substituted with one or more groups selected from halogen atom; hydroxyl group; (C1-C4) alkyl; (C3-C5) cycloalkyl; (C1-C4) alkoxy optionally substituted with a (C1-C4) alkoxy, haloalkyl, or haloalkoxy group; and nitrile group;
wherein, when X is a nitrogen atom and Y is —CR4-, then A represents said fused aryl or heteroaryl group optionally substituted with said one or more groups;
W represents a halogen atom or a haloalkyl group;
Z represents a (C1-C4) alkylene group optionally substituted with one or more groups selected from halogen atom, (C1-C4) alkyl, hydroxyl, and (C1-C4) alkoxy groups;
B represents a group —NR4R5, in which R4 and R5 represent, independently of each other, a (C1-C4) alkyl group;
either, R1 represents a hydrogen atom and R2 represents a (C1-C4) alkyl group, or R1 and R2 form, together with the carbon atom to which they are attached, a monocyclic or polycyclic system selected from a (C3-C8) cycloalkyl group, a bridged bicyclic group, and a bridged tetracyclic group, wherein said monocyclic or polycyclic system is optionally substituted with one or more hydroxyl groups;
either, R3 represents a group C(O)R5 with R5 representing a (C1-C4) alkoxy group optionally substituted with a (C1-C4) alkoxy group or a group NR6R7, with R6 and R7, independently of each other, representing a hydrogen atom or a (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkylsulfonyl or haloalkyl group,
or R3 represents a group CH2XR8 in which:
X represents an oxygen atom and R8 represents a hydrogen atom or a (C1-C4) alkyl group,
or X represents an NH group and R8 represents a (C1-C4) alkyl-carbonyl, (C1-C4) alkylcarboxyl or (C1-C4)alkylsulfonyl group,
or R3 represents a nitrile group (CN); and
p represents an integer of 0 or 1;
wherein the compound can be in the form of a base or an addition salt with an acid or a base, and enantiomers and diastereoisomers thereof, including racemic mixtures thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
R4 represents a hydrogen atom;
W represents a halogen atom;
Z represents a (C1-C4) alkylene group;
either, R1 represents a hydrogen atom and R2 represents a (C1-C4) alkyl group, or R1 and R2 form, together with the carbon atom to which they are attached, a monocyclic or polycyclic system selected from a (C3-C8) cycloalkyl group and a bridged tetracyclic group, wherein said monocyclic or polycyclic system is optionally substituted with one or more hydroxyl groups;
either R3 represents a group C(O)R5, with R5 representing a (C1-C4) alkoxy group optionally substituted with a (C1-C4) alkoxy group or a group NR6R7, with R6 and R7, independently of each other, representing a hydrogen atom or a (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkylsulfonyl, or haloalkyl group,
or R3 represents a group CH2XR8 in which X represents an oxygen atom and R8 represents a hydrogen atom or a (C1-C4) alkyl group,
or R3 represents a nitrile group (CN).

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
X represents a nitrogen atom and Y represents a nitrogen atom or —CR4-, in which R4 represents a hydrogen atom;
A represents said fused aryl, unfused aryl, or heteroaryl group, wherein said aryl or heteroaryl group is optionally substituted with one or more groups selected from halogen atom, (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkoxy, and haloalkoxy;
W represents a halogen atom;
Z represents a (C1-C4) alkylene group; and
either, R1 represents a hydrogen atom and R2 represents a (C1-C4) alkyl group, or R1 and R2 form, together with the carbon atom to which they are attached, a (C3-C8) cycloalkyl group optionally substituted with one or more hydroxyl groups or an adamantyl group;
either R3 represents a group C(O)R5 with R5 representing a (C1-C4) alkoxy group optionally substituted with a (C1-C4) alkoxy group or a group NR6R7, with R6 representing a hydrogen atom and R7 representing a hydrogen atom or a (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkylsulfonyl or haloalkyl group,
or R3 represents a group —CH2XR8 with X representing an oxygen atom and R8 representing a hydrogen atom or a (C1-C4) alkyl group.

### Claim 4 (depends on 1)

A compound of claim 1 selected from:
methyl 1-{[(3,5-dichloro-2′-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-2,3′-bipyridin-6′-yl)carbonyl]amino}cyclohexanecarboxylate;
methyl 1-{[(3-chloro-2′-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-methyl-2,3′-bipyridin-6′-yl)carbonyl]amino}cyclohexanecarboxylate;
methyl 1-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-(6-methyl-1,3-benzodioxol-5-yl)pyridin-2-yl]carbonyl}amino)cyclohexanecarboxylate;
methyl 1-{[(3-chloro-2′-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-fluoro-2,3′-bipyridin-6′-yl)carbonyl]amino}cyclohexanecarboxylate;
methyl 1-{[(2′-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-3,5-dimethyl-2,3′-bipyridin-6′-yl)carbonyl]amino}cyclohexanecarboxylate;
methyl 1-{[(2-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-2′-methyl-3,3′-bipyridin-6-yl)carbonyl]amino}cyclohexanecarboxylate;
methyl 1-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-(3,5-dimethyl-1H-pyrazol-1-yl)pyridin-2-yl]carbonyl}amino)cyclohexanecarboxylate;
methyl 1-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}5-(3,5-diethyl-1H-pyrazol-1-yl)pyridin-2-yl]carbonyl}amino)cyclohexanecarboxylate;
methyl 1-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-(2,4-dimethylphenyl)pyrazin-2-yl]carbonyl}amino)cyclohexanecarboxylate;
methyl 1-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-(2-chloro-5-ethoxyphenyl)pyrazin-2-yl]carbonyl}amino)cyclohexanecarboxylate;
methyl(3S)-3-({[6-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-(2-chloro-5-ethoxyphenyl)pyrazin-2-yl]carbonyl}amino)-4,4-dimethylpentanoate;
methyl(3S)-3-{[(3-chloro-2′-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-fluoro-2,3′-bipyridin-6′-yl)carbonyl]amino}-4,4-dimethylpentanoate;
methyl cis-1-{[(3,5-dichloro-2′-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-2,3′-bipyridin-6′-yl)carbonyl]amino}-4-hydroxycyclohexanecarboxylate; and
methyl cis-1-{[(3-chloro-2′-{4-chloro-3-[3-(dimethylamino)propoxy]phenyl}-5-methyl-2,3′-bipyridin-6′-yl)carbonyl]amino}-4-hydroxycyclohexanecarboxylate.

### Claim 5 (depends on 1)

The compound of claim 1, wherein X represents a nitrogen atom and Y represents —CR4-.

### Claim 6 (depends on 1)

The compound of claim 1, wherein A represents a heteroaryl group optionally substituted with one or more groups selected from halogen atom and (C1-C4))alkyl.

### Claim 7 (depends on 1)

A process for preparing a compound of formula (I) of claim 1, the method comprising reacting a compound of formula (II):
in which X, Y, Z, W, A, and B are as defined in claim 1, with a compound of formula (III):
in which R1, R2, R3, and p are as defined in claim 1.

### Claim 8 (depends on 1)

A process for preparing a compound of formula (I) of claim 1, the method comprising reacting a compound of formula (IV):
in which X, Y, Z, W, A, B, R1, R2, and p are as defined in claim 1, with a compound of formula R5H, wherein R5 is as defined in claim 1.

### Claim 9 (depends on 1)

A process for preparing a compound of formula (I) of claim 1, the method comprising reacting a compound of formula (IV):
in which A, Y, X, R1, R2, p, W, Z, and B are as defined in claim 1, with a reducing agent.

### Claim 10 (depends on 1)

A medicament comprising a compound of formula (I) as claimed in claim 1, or an addition salt of said compound with a pharmaceutically acceptable acid or base, or alternatively an enantiomer, a diastereoisomer or a racemic mixture of said compound.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1, or an addition salt of this compound with a pharmaceutically acceptable acid or base, an enantiomer, a diastereoisomer or a racemic mixture of this compound, and at least one pharmaceutically acceptable excipient.

### Claim 12 (depends on 1)

A method of treating and/or preventing a disorder, the method comprising administering to a patient in need thereof an effective dose of a compound of formula (I) of claim 1, wherein said disorder is selected from: congestive cardiac insufficiency, cardiac ischemia, myocardial infarction, cardiac hypertrophy and fibrosis, coronary diseases, atherosclerosis, systemic and pulmonary arterial hypertension, portal hypertension, hepatic fibrosis, post-angioplasty restenosis, acute and chronic renal insufficiency of diabetic and/or hypertensive origin, diabetes, inflammation, fibroses, aneurisms, central nervous system disorders, neurodegenerative diseases, strokes, stress, anxiety, aggressiveness, depression, schizophrenia, sleep disorders, cancers, respiratory diseases, and asthma.

### Claim 13 (depends on 1)

A method of treating and/or preventing vomiting, the method comprising administering to a patient in need thereof an effective dose of a compound of formula (I) of claim 1.
